Properties of Filament-bound Myosin Light Chain Kinase*

Pei-ju Lin, Katherine Luby-Phelps, and James T. StullDagger

From the Department of Physiology, University of Texas Southwestern Medical Center, Dallas, Texas 75235

    ABSTRACT
Top
Abstract
Introduction
References

Myosin light chain kinase binds to actin-containing filaments from cells with a greater affinity than to F-actin. However, it is not known if this binding in cells is regulated by Ca2+/calmodulin as it is with F-actin. Therefore, the binding properties of the kinase to stress fibers were examined in smooth muscle-derived A7r5 cells. Full-length myosin light chain kinase or a truncation mutant lacking residues 2-142 was expressed as chimeras containing green fluorescent protein at the C terminus. In intact cells, the full-length kinase bound to stress fibers, whereas the truncated kinase showed diffuse fluorescence in the cytoplasm. After permeabilization with saponin, the fluorescence from the truncated kinase disappeared, whereas the fluorescence of the full-length kinase was retained on stress fibers. Measurements of fluorescence intensities and fluorescence recovery after photobleaching of the full-length myosin light chain kinase in saponin-permeable cells showed that Ca2+/calmodulin did not dissociate the kinase from these filaments. However, the filament-bound kinase was sufficient for Ca2+-dependent phosphorylation of myosin regulatory light chain and contraction of stress fibers. Thus, dissociation of myosin light chain kinase from actin-containing thin filaments is not necessary for phosphorylation of myosin light chain in thick filaments. We note that the distance between the N terminus and the catalytic core of the kinase is sufficient to span the distance between thin and thick filaments.

    INTRODUCTION
Top
Abstract
Introduction
References

Phosphorylation of Ser-19 at the N terminus of smooth muscle myosin regulatory light chain (RLC)1 by Ca2+/calmodulin-dependent myosin light chain kinase results in an increase in actin-activated Mg2+ATPase activity. It is now known that this activity plays a key role in a variety of biological events, including, in part, initiation of smooth muscle contraction (1), potentiation of skeletal and cardiac muscle contraction (2), fibroblast contraction (3, 4), endothelial cell retraction (5-7), platelet aggregation and contraction (8, 9), growth cone motility in nerve cells (10), and receptor capping in lymphocytes (11). When the intracellular Ca2+ concentration increases upon stimulation of cells by Ca2+ influx through Ca2+ channels in the plasma membrane or through Ca2+ release from intracellular Ca2+ stores, Ca2+ binds to calmodulin. Ca2+/calmodulin binds to the calmodulin-binding sequence of the kinase, resulting in displacement of the autoinhibitory segment and exposure of the catalytic site for RLC phosphorylation (12, 13).

Previous studies in vitro showed that myosin light chain kinase binds to purified F-actin as well as myosin filaments and that binding in both cases is regulated by Ca2+/calmodulin (14-18). Biochemical studies by co-sedimentation assays in vitro indicated that the N terminus of myosin light chain kinase was responsible for binding to purified F-actin (14-16), whereas its C terminus bound to purified myosin (17, 18) with binding affinities in the range of 10-5 to 10-6 M. These binding affinities were decreased in the presence of Ca2+/calmodulin (18). Additionally, Ca2+/calmodulin may interact with an N-terminal F-actin-binding site of myosin light chain kinase, distinct from the calmodulin-binding sequence at the C terminus of the catalytic core (15). The F-actin binding site in residues 1-41 had a Ka value of approximately 105 M-1 with an IQ-like sequence in residues 26-41 that bound calmodulin (15).

Studies have also shown that myosin light chain kinase binds to cellular actomyosin-containing filaments. Immunocytochemistry studies found myosin light chain kinase localized to actomyosin-containing stress fibers or myofilaments in nonmuscle and smooth muscle cells, respectively (19, 20). Recent investigations in vitro and in vivo showed that the N-terminal half of the kinase (residues 1-655), not the C terminus, was both necessary and sufficient for binding to isolated smooth muscle myofilaments, stress fibers in permeabilized fibroblasts, and myofilaments in intact smooth muscle cells (21). In addition, the apparent binding affinities of myosin light chain kinase to smooth muscle myofilaments and actin-containing thin filaments were greater than to purified smooth muscle F-actin and skeletal muscle myofilaments (21, 22). Thus, myosin light chain kinase binds to actomyosin-containing filaments or actin-containing thin filaments in cells with an affinity greater than to F-actin alone, perhaps due to the presence of a distinct anchoring protein or a protein that facilitates binding to F-actin.

Other reports support the idea that myosin light chain kinase binds tightly to actomyosin-containing filaments in cells or tissues. For example, smooth muscle tissue strips made permeable with 1% Triton X-100 and stored for several weeks at -20 °C in 50% glycerol were still able to contract in the presence of Mg2+ATP and Ca2+/calmodulin (23). Quantitation of myosin light chain kinase showed no significant loss of the kinase after storage. Thus, myosin light chain kinase appears to bind tightly to myofilaments in permeable smooth muscle cells with an apparent affinity greater than values reported for binding to purified F-actin (21). This raises the question of whether myosin light chain kinase must dissociate from actin-containing thin filaments to phosphorylate myosin RLC in the thick filaments (14-18). Stimulation of smooth muscle tissues can result in a high extent (50-100%) of RLC phosphorylation, particularly in the presence of a cell-permeable protein phosphatase inhibitor (24-27). Yet, the concentration of RLC in smooth muscle is estimated as 75-80 mM, a concentration 25 times greater than the concentration of myosin light chain kinase (28, 29). Smooth muscle myosin light chain kinase associated with actin-containing filaments may thus dissociate and diffuse to myosin-containing filaments to achieve a high extent of RLC phosphorylation during contraction (14). Thus, Ca2+/calmodulin may not only activate the kinase but also dissociate it from actin-containing filaments via interaction with a second binding site in the N terminus (15). To test this hypothesis, we transiently expressed myosin light chain kinase with green fluorescent protein and established a system to study its binding to stress fibers in permeable A7r5 cells derived from smooth muscle.

    EXPERIMENTAL PROCEDURES

Myosin Light Chain Kinase Binding to Smooth Muscle Myofilaments and F-actin on Nitrocellulose-coated Coverslips-- Extracted smooth muscle myofilaments and purified F-actin filaments (21) were diluted to 1 mg/ml in air-dried BODIPY FL phallacidin (5 units, Molecular Probes, Inc., Eugene, OR) containing 10 mM MOPS at pH 7.0, 50 mM NaCl, 2 mM dithiothreitol, 1 mg/ml bovine serum albumin, and 1 mM MgCl2. After adding to nitrocellulose-coated coverslips (advice kindly provided by Dr. Joseph Haeberle, University of Vermont) at room temperature for 30 min, the coverslips were washed with buffer three times to remove nonadhering filaments. Cy3-labeled full-length myosin light chain kinase (0.2 mM) (21) was added to both types of filaments. After incubation at room temperature for 10 min, coverslips were washed with buffer three times to remove unbound kinase. Coverslips were sealed on glass slides for fluorescence imaging.

Construction of MLCK-GFP Plasmids-- MLCK-GFP expression vectors were constructed from modified pGREEN LANTERNTM-1 (Life Technologies, Inc.), a cytomegalovirus promoter-driven expression vector containing GFP coding sequences. This GFP coding sequence contains a Ser65 right-arrow Thr mutation and "humanized" codon usage for increasing its brightness and better expression in mammalian cells (30). Plasmid pGREEN LANTERNTM-1 was modified to delete two nucleotides (GC) between SpeI and NotI cloning sites. This modification shifts an in frame TAG stop codon (within the SpeI restriction enzyme site) at the 5'-end of GFP coding sequences to out of frame. A two-nucleotide-deleted SpeI-BclI GFP DNA fragment (1 kilobase pair) was synthesized by polymerase chain reaction using pGREEN LANTERNTM-1 as a template and a primer pair: 5'-GCTGACTAGTGCGGCCGCCGCCAC-3' and 5'-GGCTGATTATGATCATGAAC-3'. This polymerase chain reaction DNA fragment and vector pGREEN LANTERNTM-1 were digested with SpeI and BamHI sites. The 0.54- and 4.5-kilobase-paired DNA fragments from the digested polymerase chain reaction product and the vector, respectively, were ligated and transformed. The modified plasmid (pGFP) was confirmed by DNA sequencing and further used to construct MLCK-GFP fusion protein expression vectors. Full-length and N-terminal (amino acids 2-142) deleted myosin light chain kinase DNA fragments were synthesized without a stop codon at their 3'-ends by polymerase chain reaction using Pat1/J1-J3 (containing full-length rabbit smooth muscle myosin light chain kinase coding sequences) as a template and primer pairs 5'-TCCCCCCGGGATGGATTTCCGCGCCAAC-3' and 5'-GACTAGTTGACTCCTCTTCCTCCTCTTCCCC-3', and 5'-TCCCCCCGGGATGGAGAGCTCGAAACCTGTGGGC-3' and 5'-GACTAGTTGACTCCTCTTCCTCCTCTTCCCC-3', respectively. Synthesized myosin light chain kinase DNA fragments (3.6 and 3.0 kilobase pairs) were ligated into pGFP by XmaI and SpeI sites. The resultant plasmids (pFL-GFP and pDN-GFP) were confirmed by restriction enzyme analyses and DNA sequencing.

Cell Culture and DNA Transfection-- A7r5 rat thoracic aorta smooth muscle cells (obtained from ATCC, CRL-1444) were maintained in Dulbecco's modified Eagle's medium containing 4 mM L-glutamine, 1.5 g/liter sodium bicarbonate, 4.5 g/liter glucose, 1 mM sodium pyruvate, 10% fetal bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin at 37 °C with 5% CO2. For DNA transfection, A7r5 cells were seeded onto 40-mm round coverslips (40 Circles-1D; Fisher) in 60-mm Petri dishes at 30-50% confluence 1 day before transfection. DNA was transfected by a liposome-mediated method according to the manufacturer's instructions. In brief, 12 ml of FuGENETM-6 (Boehringer Mannheim) was added into 288 ml of serum-free medium. After a 5-min incubation at room temperature, the FuGENETM-6/medium mixture was added slowly to 3 mg of DNA (15 ml of 0.2 mg/ml DNA). After a 15-min incubation at room temperature, the FuGENETM-6/DNA mixture was added to cells. Transfected cells were incubated for 2 days before experiments.

Determination of Myosin Light Chain Kinase Activity and Binding in Vitro-- Ca2+/calmodulin-dependent activity of myosin light chain kinase was determined by measuring rates of 32P incorporation into myosin RLC (31). Transfected or untransfected cells were lysed on ice for 10 min in 50 mM MOPS at pH 7.0, 50 mM MgCl2, 0.5 mM EGTA, 1% Nonidet P-40, 10% glycerol, 1 mM dithiothreitol, and protease inhibitors (100 mg/ml phenylmethylsulfonyl fluoride, 20 mg/ml leupeptin, 30 mg/ml aprotenin, 60 mg/ml tosyllysylchlomethyl ketone, and 60 mg/ml tosylphenylalanyl chloromethyl ketone). Cell lysates were clarified by centrifugation at 14,000 × g for 2 min and diluted for kinase activity assays so that 32P incorporation was linear in respect to time. The minimal kinase activities from untransfected cells were measured as background values. The amounts of expressed MLCK-GFP proteins were quantitated by immunoblotting using either monoclonal antibodies raised to the full-length myosin light chain kinase or polyclonal antibodies raised against the catalytic core of rabbit smooth muscle myosin light chain kinase. Various amounts of rabbit smooth muscle myosin light chain kinase purified from Sf9 cells (21) were used for a standard curve.

For binding analyses in vitro, A7r5 cell lysates containing expressed myosin light chain kinase were further dialyzed against 50 mM MOPS at pH 7.0, 0.5 mM EGTA, 10% glycerol, 1 mM dithiothreitol, and protease inhibitors to remove MgCl2. Binding of myosin light chain kinases to smooth muscle myofilaments in vitro was measured by a co-sedimentation procedure (21). The amounts of myosin light chain kinase in the supernatant and pellet fractions were compared by measurements of kinase activity.

Measurement of the Amount of Expressed MLCK-GFP in A7r5 Cells-- A7r5 cells transfected with cDNA for MLCK-GFP were sorted by flow cytometry (FACStar Plus; Becton Dickinson, San Jose, CA). After cells were detached by 0.05%/0.53 mM trypsin-EDTA (Life Technologies, Inc.), fetal bovine serum was added to inhibit trypsin activity. Cells were centrifuged at 200 × g for 10 min and washed with phosphate-buffered saline twice before sorting. Cells were sorted based on fluorescence intensity (excitation at 488 nm). About 15% transfected A7r5 cells showed green fluorescence. Positive (fluorescent) and negative (nonfluorescent) cells were collected separately. Numbers of the collected cells after sorting were recorded. Cells were lysed, and the amount of expressed MLCK-GFP was measured by immunoblotting as described previously herein. The average concentration of expressed MLCK-GFP in a single cell was calculated as follows: amount of MLCK-GFP/(number of cells × volume of a single cell). The volume of a single cell was assumed to be 2 picoliters.

Ca2+/EGTA Buffers and Cell Permeabilization-- Ca2+-free buffer contained 20 mM PIPES, 4 mM EGTA, 5 mM MgSO4, 90 mM K+-gluconate, 5.3 mM Na2ATP, 0.1% bovine serum albumin, 0.1 mM ionomycin (Calbiochem), 1.5 mM thapsigargin (Sigma), 0.1 mM phenylmethylsulfonyl fluoride (Sigma), and 10 mg/ml leupeptin (Sigma) at pH 6.8 (23). Concentrated Ca2+ solutions buffered with Ca2+-free buffer (containing 4 mM EGTA) were used to achieve free [Ca2+] of 1 mM and 10 mM. Buffers containing 1 and 10 mM [Ca2+] were measured and calibrated with the Ca2+ indicators fluo-3 and calcium green-5N (Molecular Probes), respectively. A7r5 cells were treated with 0.02% saponin in the Ca2+-free, 1 mM [Ca2+], 100 nM calmodulin or the 10 mM [Ca2+], 1 mM calmodulin, 10 mM wortmannin buffer at 37 °C for 10 min. After treatment, the permeable cells were washed with the buffer without saponin for three times and/or treated with the indicated buffers.

Fluorescence Imaging-- Fluorescence imaging was performed as described previously (32). Twelve-bit fluorescence images were acquired by a cooled CCD camera (Quantix Photometrics, Tucson, AZ) and Oncor-Image software (Oncor, Gaithersburg, MD). Narrow bandpass interference filters (Omega, Brattleboro, VT) were used to select BODIPY fluorescein or GFP (excitation at 490 nm and emission at 520 nm) and rhodamine or Cy3 (excitation at 550 nm and emission at 575 nm) fluorescence. Cells were kept in an open thermal controlled chamber (Custom Scientific, Dallas, TX) at 37 °C during fluorescence imaging. Additional imaging experiments were performed with purified F-actin and detergent-washed gizzard myofilaments with Cy3-labeled myosin light chain kinase (21).

Fluorescence Recovery after Photobleaching (FRAP)-- FRAP was performed on the saponin-permeable A7r5 cells as described previously (23) with the following modification. An argon ion laser (Spectra-Physics 2017) operated at 1 watt on the 488 nm line was directed into the microscope (Zeiss Axiovert 35) with the beam radius 4.43 mm at the specimen plane. The proportion of the cell photobleached was approximately 3%. Photobleaching time was 2-30 ms, resulting in a 20-70% decrease in the fluorescence intensity. At least three half-lives of data were recorded for each recovery. The recovery time for some experiments was monitored for 15 min. Cells were maintained at 37 °C in a sealed chamber. A control experiment using A7r5 cells microinjected with 167-kDa fluorescein-labeled dextran (Sigma; 4 mg/ml in 10 mM MOPS, 30 mM magnesium acetate, 100 mM NaCl at pH 7.1) was also included in FRAP measurements under similar conditions, except the cells were permeabilized with 30 mg/ml beta -escin at 37 °C for 10 min (23).

Measurement of RLC Phosphorylation by Urea-Glycerol PAGE-- A7r5 cells were treated with 0.02% saponin in Ca2+-free buffer at 37 °C for 10 min and washed with Ca2+-free buffer three times. After washing, permeable cells were treated with various buffers at room temperature for 3 or 30 min: Ca2+-free buffer, Ca2+ buffer alone, Ca2+ buffer plus 10 mM wortmannin (Sigma), and Ca2+ buffer plus 4 mM concentraetion of a peptide (KKRAARATSNVFS-amide, synthesized by Genosys Biotechnologies, Inc.) containing the sequence around the phosphorylatable serine in the smooth muscle RLC (33), respectively. The Ca2+ buffer solution included 10 mM Ca2+ and 100 nM calmodulin with or without 3 mM okadaic acid, a protein phosphatase type 1 and 2A inhibitor (Calbiochem). In addition to other chemicals described above, after treatments the solutions were aspirated completely. Ice-cold 10% trichloroacetic acid and 10 mM dithiothreitol were added, and cells were frozen by putting culture dishes into liquid nitrogen immediately. Cell protein was collected and incubated on ice for 20 min, and insoluble proteins were collected by centrifugation at 4,700 × g for 1 min. Pellets were washed with ethyl ether (Fisher) three times and resuspended in 8 M urea sample buffer as described previously (34). The samples were analyzed by urea-glycerol PAGE and immunoblotting using a monoclonal antibody against smooth muscle RLC (34). The relative amounts of nonphosphorylated, monophosphorylated, and diphosphorylated RLCs were measured by quantitative immunoblots.

    RESULTS

Myosin Light Chain Kinase Binding to Smooth Muscle Myofilaments and F-actin on Nitrocellulose-coated Coverslips-- Extracted smooth muscle myofilaments and purified smooth muscle F-actin mixed with BODIPY FL phallacidin were bound to nitrocellulose-coated coverslips. Cy3-labeled myosin light chain kinase was added to the filaments to test its binding ability. Fig. 1 shows phallacidin binding to actin in both smooth muscle myofilaments and smooth muscle F-actin. The Cy3-labeled myosin light chain kinase strongly bound only to smooth muscle myofilaments (Fig. 1). These results are similar to previous results obtained with a cosedimentation assay where myosin light chain kinase bound to gizzard smooth muscle myofilaments with a greater affinity compared with purified smooth muscle F-actin (21).


View larger version (58K):
[in this window]
[in a new window]
 
Fig. 1.   Myosin light chain kinase binding to smooth muscle myofilaments and F-actin on nitrocellulose-coated coverslips. Extracted smooth muscle myofilaments and purified F-actin filaments (1 mg/ml) were mixed with BODIPY FL phallacidin (5 units; Molecular Probes) in a buffer containing 10 mM MOPS at pH 7.0, 50 mM NaCl, 2 mM dithiothreitol, 1 mg/ml bovine serum albumin, and 1 mM MgCl2 to identify actin-containing filaments. The respective filamentous solutions were adhered to nitrocellulose-coated coverslips, and Cy3-labeled full-length myosin light chain kinase was added. After incubation for 10 min, coverslips were washed three times to remove the unbound kinase. Filaments were double imaged under a fluorescence microscope to detect BODIPY fluorescein and Cy3 fluorescence (for details, see "Experimental Procedures"). Typical fluorescence micrographs are presented for three experiments.

Expression and Biochemical Properties of MLCK-GFP in Intact A7r5 Smooth Muscle Cells-- To study the physiological effects and binding properties of myosin light chain kinase in cells, MLCK-GFP fusion protein expression vectors were constructed. The cDNA encoding GFP was fused at the C terminus of full-length (FL) or N-terminal deleted (DN) myosin light chain kinase (Fig. 2A). The N-terminal 2-142 amino acids were deleted in DN MLCK-GFP. This region is within the N-terminal half of the kinase, which is responsible for high affinity myofilament binding in vitro and in vivo (21) and contains the actin binding segment (14-16). GFP, FL MLCK-GFP, and DN MLCK-GFP were transiently expressed in A7r5 smooth muscle cells (Fig. 2B). As expected, fluorescence from the 27-kDa GFP was diffuse and was found in both the nucleus and cytoplasm in transfected cells (Fig. 2B, left part). The 153-kDa FL MLCK-GFP was localized primarily to filaments with some diffuse cytoplasmic fluorescence (Fig. 2B, middle part). The amount of diffuse cytoplasmic fluorescence was greater in cells expressing larger amounts of the kinase. The 137-kDa DN MLCK-GFP showed only diffuse fluorescence in the cytoplasm without apparent binding to filaments (Fig. 2B, right part). Both FL MLCK-GFP and DN MLCK-GFP were excluded from nuclei, most likely due to their masses. MLCK-GFP with deletion of the kinase C terminus (amino acids 1004-1147) was also expressed and found primarily on filaments similar to FL MLCK-GFP (data not shown). These results show that the site for high affinity binding resides in residues 2-142 and that the GFP tag at the C terminus of full-length myosin light chain kinase did not affect kinase binding to stress fibers in cells. Similar results were also obtained in transfected NIH 3T3 and CV1 fibroblast cells (data not shown).


View larger version (66K):
[in this window]
[in a new window]
 
Fig. 2.   Expression of myosin light chain kinases with green fluorescent protein. A, scheme of domain organization of myosin light chain kinases with green fluorescent protein at the C terminus. Plasmids carrying the coding sequences of GFP and MLCK-GFP fusion proteins were constructed as described under "Experimental Procedures." The regulatory segment contains the respective autoinhibitory and calmodulin-binding sequences. Ig-1, Ig-2, and Ig-3, immunoglobulin C2-like motifs; Fn, fibronectin type III-like motif. B, transient expression of GFP, FL MLCK-GFP, and DN MLCK-GFP in A7r5 cells. DNA was transiently transfected into A7r5 cells and fluorescence images obtained as described under "Experimental Procedures."

The specific activity of FL MLCK-GFP from transfected cell lysates was compared with full-length myosin light chain kinase purified from Sf9 cells (Fig. 3A). The kinase activity of FL MLCK-GFP was Ca2+/calmodulin-dependent, and the specific activity was 1280 pmol/min/pmol, comparable with that of purified full-length myosin light chain kinase without GFP (1980 pmol/min/pmol). The ability of FL MLCK-GFP to bind to smooth muscle myofilaments in vitro was also measured by the co-sedimentation assay. Cell lysates containing 5 nM FL MLCK-GFP were used to compare the binding ability with purified full-length myosin light chain kinase to detergent-washed myofilaments from gizzard smooth muscle (Fig. 3B). Myosin light chain kinase with or without GFP bound smooth muscle myofilaments similarly under these conditions. Thus, the introduction of green fluorescent protein at the C terminus of myosin light chain kinase had no significant effect on kinase catalytic or binding properties. These results indicate that the FL MLCK-GFP may be used to characterize the cellular binding properties of myosin light chain kinase in cells.


View larger version (23K):
[in this window]
[in a new window]
 
Fig. 3.   Specific activity and binding of FL MLCK-GFP in A7r5 cells. Purified full-length myosin light chain kinase from Sf9 cells (21) and cell lysates from A7r5 cells expressing FL MLCK-GFP were used for measurements of kinase activity and binding to detergent-washed smooth muscle myofilaments. A, specific activity of FL MLCK-GFP. Kinase activities were measured by rates of 32P incorporation into myosin RLC in the presence of 4 mM EGTA (- Ca2+/CaM, open bar) or 0.3 mM CaCl2 and 1 mM calmodulin (+ Ca2+/CaM, hatched bar) (31). The amount of expressed MLCK-GFP protein was quantitated by immunoblotting as described under "Experimental Procedures." B, binding of 5 nM myosin light chain kinases to smooth muscle myofilaments in vitro. Binding of purified full-length smooth muscle myosin light chain kinase (filled circle) and 5 nM FL MLCK-GFP in cell lysates (open circle) to smooth muscle myofilaments in vitro was measured by a co-sedimentation procedure (21). The concentration of actin in smooth muscle myofilaments was measured by densitometric scanning after SDS-PAGE. The amounts of myosin light chain kinase in the supernatant and pellet fractions were compared by measurements of kinase activity. The data represent the means ± S.E. for three experiments.

The concentration of expressed FL MLCK-GFP in a single A7r5 cell was estimated by flow cytometry and immunoblotting (data not shown). The estimated FL MLCK-GFP concentration was 1.1 ± 0.3 mM, which is in a range similar for the endogenous myosin light chain kinase in smooth muscle cells in tissues (3-4 mM), although it is at least 10 times greater than the amounts found in nonmuscle cells (35).

Myosin Light Chain Kinase Binding in Permeable A7r5 Cells-- To examine Ca2+ regulation of myosin light chain kinase binding to cellular actomyosin filaments, transfected A7r5 cells were made selectively permeable by saponin. A7r5 cells were transfected with DN MLCK-GFP or FL MLCK-GFP and intact cells were imaged (Fig. 4, top panels). After treatment with saponin for 10 min, the diffuse cytoplasmic fluorescence due to DN MLCK-GFP was completely removed, indicating release of the kinase from cells (Fig. 4, middle left panel). This was not due to loss of actin-containing stress fibers as shown by staining with rhodamine-labeled phalloidin (Fig. 4, bottom left panel). In the FL MLCK-GFP-transfected A7r5 cells, the diffuse fluorescence was released from the cells by saponin treatment, while the filament-associated FL MLCK-GFP remained (Fig. 4, middle right panel).


View larger version (101K):
[in this window]
[in a new window]
 
Fig. 4.   Myosin light chain kinase binding in permeable A7r5 cells. DN MLCK-GFP (left panels) and FL MLCK-GFP (right panels) in transfected A7r5 cells were imaged before permeabilization (Intact, top panels). After imaging the intact cells, cells were treated with 0.02% saponin in Ca2+-free buffer (20 mM PIPES at pH 6.8, 4 mM EGTA, 5 mM MgSO4, 90 mM K+-gluconate, 5.3 mM Na2ATP, 0.1% bovine serum albumin, 0.1 mM ionomycin, 1.5 mM thapsigargin, 0.1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml leupeptin) at 37 °C for 10 min. After permeabilization, cells were washed three times with the Ca2+-free buffer without saponin, and the same cells were imaged (Saponin, middle panels). Rhodamine-labeled phalloidin was added to the Ca2+-free buffer for 2 min and then washed with the Ca2+-free buffer three times following by imaging (phalloidin, bottom panels).

Effect of Ca2+/Calmodulin on Myosin Light Chain Kinase Binding to Filaments in Permeable Cells-- To test whether Ca2+/calmodulin affects myosin light chain kinase binding in cells, fluorescence intensities of FL MLCK-GFP bound to filaments in saponin-permeable cells were compared in the presence of either 4 mM EGTA or 10 mM Ca2+ plus 1 mM calmodulin and 10 mM wortmannin (Fig. 5A). Although calmodulin is not completely removed from cellular filaments by EGTA (23), calmodulin was added to the buffer containing Ca2+ to assure a sufficient amount for binding to the kinase. Wortmannin was added to the Ca2+-containing buffer to prevent the robust contraction of cell filaments for fluorescence measurements. Cells were either treated with EGTA buffer first and then washed with the Ca2+/calmodulin/wortmannin buffer or treated with Ca2+/calmodulin/wortmannin buffer first and then washed with the EGTA buffer. The fluorescence intensities of FL MLCK-GFP remained unchanged in both circumstances (Fig. 5A). Similar results were obtained by comparison with EGTA buffer and 1 mM Ca2+/100 nM calmodulin buffer (data not shown). Thus, myosin light chain kinase binding to actin-containing stress fibers is not released by Ca2+/calmodulin.


View larger version (18K):
[in this window]
[in a new window]
 
Fig. 5.   Effect of Ca2+/calmodulin on myosin light chain kinase binding to filaments in permeable A7r5 cells. A, measurements of fluorescence intensities of filament-bound FL MLCK-GFP in saponin-permeable A7r5 cells in the presence of 4 mM EGTA Ca2+-free buffer (open bar) or 10 mM Ca2+/1 mM calmodulin/10 mM wortmannin buffer (closed bar). Cells were either treated with the EGTA buffer first and then washed with the Ca2+/calmodulin/wortmannin buffer (left) or treated with the Ca2+/calmodulin/wortmannin buffer first and then washed with the EGTA buffer (right). Fluorescence intensities were measured as described under "Experimental Procedures." Fluorescence intensities in the same areas of the cells were monitored for 5 s at 500-ms intervals. The fluorescence intensities after buffer changes were normalized to the fluorescence intensities before buffer changes. The fluorescence intensities were calculated as means ± S.E. from three experiments. B, fluorescence recovery after photobleaching of filament-bound FL MLCK-GFP (solid symbols) and 167-kDa fluorescein-labeled dextran (open symbols) in the presence of Ca2+-free buffer (circle, solid line) or 10 mM Ca2+, 1 mM calmodulin, 10 mM wortmannin buffer (square, dashed line). Eight to fifteen samples from three individual experiments were tested. A typical FRAP experiment is presented.

To test whether myosin light chain kinase may diffuse laterally along filaments, the mobility of FL MLCK-GFP was examined in the saponin-permeable A7r5 cells by FRAP (Fig. 5B, closed symbols). After photobleaching, there was no recovery of fluorescence for up to 15 min, indicating that FL MLCK-GFP bound to filaments with no evidence of mobility. There was no fluorescence recovery in either EGTA buffer or 10 mM Ca2+, 1 mM calmodulin, 10 mM wortmannin after photobleaching. Similar results were obtained with the addition of 1 mM Ca2+, 100 nM calmodulin buffer for 80 s (data not shown). Additionally, similar results for measurements of fluorescence intensities and FRAP were obtained by perfusion of Cy3-labeled myosin light chain kinase in Triton X-100-permeable stress fibers in Swiss 3T3 cells (data not shown). In contrast, the fluorescence of 167-kDa fluorescein-labeled dextran in beta -escin-permeable cells was recovered 100% in 1 min after photobleaching in either EGTA or Ca2+/calmodulin (Fig. 5B, open symbols). These data collectively indicate that myosin light chain kinase binds to actin-containing filaments with high affinity and does not dissociate or diffuse along the filaments in the presence of Ca2+/calmodulin.

Cell Contraction and RLC Phosphorylation-- To determine if filament-bound myosin light chain kinase could phosphorylate myosin RLC in thick filaments in cells, cell contractility was first measured in the presence of Ca2+. Fig. 6A (top to bottom parts) shows intact cells transfected with FL MLCK-GFP, followed by saponin-permeabilization in Ca2+-free buffer containing Mg2+ATP. The subsequent addition of Ca2+ in the presence of Mg2+ATP results in contraction of filaments containing bound-myosin light chain kinase. This Ca2+-dependent contraction was inhibited in the presence of 10 mM wortmannin, a myosin light chain kinase inhibitor (Fig. 6B), or 4 mM RLC peptide, a competitive substrate (Fig. 6C).


View larger version (132K):
[in this window]
[in a new window]
 
Fig. 6.   Ca2+-dependent contraction in saponin-permeable A7r5 cells. FL MLCK-GFP-transfected A7r5 cells were imaged before permeabilization (Intact Cell, top panels). Cells were then treated with 0.02% saponin in the Ca2+-free buffer (20 mM PIPES at pH 6.8, 4 mM EGTA, 5 mM MgSO4, 90 mM K+-gluconate, 5.3 mM Na2ATP, 0.1% bovine serum albumin, 0.1 mM ionomycin, 1.5 mM thapsigargin, 0.1 mM phenylmethylsulfonyl fluoride, and 10 mg/ml leupeptin) at 37 °C for 10 min. After permeabilization, cells were washed with the Ca2+-free buffer without saponin three times, and the same cells were imaged (Ca2+ free, middle panels). Cells were further incubated with 10 mM Ca2+ buffer (A, bottom part) or 10 mM Ca2+ buffer containing either 10 mM wortmannin (B, bottom part) or 4 mM RLC peptide (C, bottom part).

To determine whether RLC phosphorylation mediates this Ca2+-dependent contraction by the filament-bound kinase, RLC phosphorylation was measured in the saponin-permeabilized cells (Fig. 7). Nonphosphorylated, monophosphorylated, and diphosphorylated RLCs were separated by urea-glycerol PAGE and measured by immunoblotting (Fig. 7A). As expected, RLC phosphorylation in saponin-permeable cells in Ca2+-free buffer alone for 3 min was low (Fig. 7, A and B). When a protein phosphatase inhibitor, okadaic acid, was added to the Ca2+-free buffer, RLC phosphorylation increased from 0.14 to 0.43 mol of phosphate/mol of RLC. When wortmannin was added with okadaic acid to the Ca2+-free buffer for 3 min, RLC phosphorylation was similar (0.41 mol of phosphate/mol of RLC) to the extent of phosphorylation obtained with okadaic acid alone (Fig. 7, A and B). Thus, there was apparently some myosin light chain kinase-independent phosphorylation of RLC. However, inclusion of 10 mM Ca2+ and 100 nM calmodulin with okadaic acid resulted in a greater extent of RLC phosphorylation, 0.87 mol of phosphate/mol of RLC (Fig. 7, A and B). This Ca2+/calmodulin-dependent RLC phosphorylation was abolished by wortmannin or RLC peptide (0.40 and 0.25 mol of phosphate/mol of RLC, respectively) (Fig. 7, A and B). When the RLC peptide substrate concentration was 50-fold in excess of RLC in a typical kinase assay, the myosin light chain kinase activity toward RLC was inhibited greater than 90% (data not shown).


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 7.   RLC phosphorylation by filament-bound myosin light chain kinase in permeable A7r5 cells. FL MLCK-GFP-transfected A7r5 cells were permeabilized with 0.02% saponin in Ca2+-free buffer at 37 °C for 10 min and washed with Ca2+-free buffer three times. After washing, cells were treated at room temperature for 3 or 30 min with Ca2+-free buffer or 10 mM Ca2+ buffer containing the following components: 3 mM okadaic acid, 10 mM wortmannin, and 4 mM RLC peptide. A, representative immunoblots of RLC phosphorylation after urea-glycerol PAGE. Migrations of the nonphosphorylated (non-P), monophosphorylated (mono-P), and diphosphorylated (di-P) forms of RLC are indicated. Lanes 1-9 correspond to the conditions in B from left to right. B, quantitation of phosphorylated RLC. The data represent the means ± S.E. for three or four experiments.

In the absence of Ca2+, RLC phosphorylation was 0.17 mol of phosphate/mol of RLC at 30 min after saponin treatment, results similar to those obtained at 3 min (Fig. 7, A and B). In the presence of Ca2+/calmodulin but in the absence of okadaic acid, the extent of RLC phosphorylation increased to 0.60 mol of phosphate/mol of RLC at 30 min. This value increased to 1.60 mol of phosphate/mol of RLC when okadaic acid was added (Fig. 7, A and B). These results suggest that filament-bound myosin light chain kinase phosphorylates myosin RLC to initiate cell contraction.

    DISCUSSION

Previous investigations showed that myosin light chain kinase bound to F-actin and F-actin-containing filaments in cells (14-20). Although it was assumed the binding in cells was to F-actin, a recent report indicated a significant difference in apparent affinities for the two types of filaments (21). Using a cosedimentation assay, Lin et al. (21) showed that the kinase binding affinity was greater for detergent-washed smooth muscle myofilaments compared with purified F-actin or detergent-washed myofilaments from skeletal muscle. This observation was extended herein with fluorescence imaging of Cy3-labeled kinase binding to purified F-actin or gizzard myofilaments. Myosin light chain kinase bound to gizzard myofilaments with no significant binding to F-actin. These results are consistent with high affinity binding of the kinase to myofilaments, perhaps due to an anchoring or accessory protein. They also raise a question as to whether this binding is regulated by Ca2+/calmodulin like the low affinity binding of kinase to purified F-actin.

A fusion protein containing myosin light chain kinase and GFP (MLCK-GFP) was expressed to monitor kinase binding to actin-containing filaments in cells. It has similar catalytic and binding properties as purified smooth muscle myosin light chain kinase and therefore may be used to characterize binding of myosin light chain kinase to actin-containing stress fibers in cells. FL MLCK-GFP, although primarily localized to the filaments in intact cells, showed some diffuse cytoplasmic fluorescence that depended on the extent of expression. This cytoplasmic fluorescence may be due to saturation of kinase binding sites on stress fibers in A7r5 cells, which is supported by the observations that it diffused out when cells were treated with saponin. Smooth muscle cells in tissues have a greater capacity for binding myosin light chain kinase, because previous reports showed that the kinase bound completely to skinned fibers (23) or detergent-washed myofilaments (36). The FL MLCK-GFP on actin-containing filaments remains bound after saponin permeabilization. These results obtained from MLCK-GFP-transfected A7r5 cells are similar to those in Triton X-100-permeable fibroblasts and intact smooth muscle cells perfused or microinjected with Cy3-labeled myosin light chain kinases (herein, and see Ref. 21).

Binding of myosin light chain kinase to actin-containing filaments in permeable cells is not affected by Ca2+/calmodulin based on the comparison of fluorescence intensities in the presence or absence of Ca2+/calmodulin. In addition, FRAP measurements in permeable cells indicate that myosin light chain kinase does not diffuse laterally along the filaments. Previous studies in vitro showed the binding affinity of myosin light chain kinase for purified F-actin or purified myosin was decreased in the presence of Ca2+/calmodulin (15, 18). Additionally, Ca2+/calmodulin also decreased the binding affinity of the N-terminal fragment (1-114 residues) of the kinase for purified F-actin and another potential Ca2+/calmodulin binding site was localized within the N-terminal actin binding sequence (residues 26-41) (15). However, the binding affinities (105 to 106 M-1) of myosin light chain kinase and its actin binding sequence for F-actin alone are low (14, 15, 18) relative to the almost irreversible binding of the kinase in skinned fibers (23) and detergent-washed myofilaments (21, 36) from smooth muscles. Deletion of the N-terminal 142 residues of MLCK-GFP prevents binding to actin-containing filaments in cells consistent with previous results (21) when the N-terminal half of myosin light chain kinase was deleted. These results indicate that a recently identified Ca2+/calmodulin-insensitive binding site in myosin light chain kinase (residues 319-721 preceding the catalytic core; Ref. 15) is not responsible for binding to filaments in cells. These results also show that the anchoring motif is in the N terminus of myosin light chain kinase. Importantly, this high affinity binding of myosin light chain kinase to actin-containing filaments in saponin-permeable A7r5 cells and in Triton X-100-permeable Swiss 3T3 fibroblasts was not affected by Ca2+/calmodulin. Although Ca2+/calmodulin is required for activation of catalysis, it does not significantly dissociate myosin light chain kinase from cellular filaments.

Filament-bound myosin light chain kinase in saponin-permeabilized cells is sufficient for RLC phosphorylation and cell contraction in the presence of Ca2+/calmodulin. Wortmannin and a competitive peptide substrate inhibited Ca2+-dependent RLC phosphorylation and smooth muscle cell contraction in saponin-permeable cells. Previous studies have shown that wortmannin is a potent and selective inhibitor for myosin light chain kinase and phosphatidylinositol 3-kinase, which is involved in formation of inositol 1,4,5-trisphosphate and Ca2+ signaling (37, 38). However, in experiments reported here, inhibition of phosphatidylinositol 3-kinase is not an important consideration, since this kinase does not phosphorylate myosin RLC, and a permeable cell system was used so that filament-bound myosin light chain kinase could be activated directly by the addition of Ca2+ and calmodulin. Wortmannin has little or no effect on the activities of other kinases including protein kinase C, cAMP-dependent protein kinase, cGMP-dependent protein kinase, calmodulin-dependent protein kinase II, tyrosine kinases, and phosphatidylinositol 4-kinase (37, 38). In saponin-permeabilized cells, both wortmannin and RLC peptide inhibited Ca2+-dependent RLC phosphorylation and cell contraction, which is consistent with the idea that these coupled events (3-7) are due to filament-bound myosin light chain kinase.

In our studies, three forms (non-, mono-, and diphosphorylated) of RLC were observed in saponin-permeable cells in the presence of Ca2+/calmodulin and/or okadaic acid. Phosphorylation at Ser-19 of smooth muscle myosin RLC by myosin light chain kinase has been identified both in vitro and in smooth muscle tissues as the major monophosphorylation site important for actin-activated MgATPase activity and myosin motility (25, 39). However, Thr-18 is also phosphorylated but at a slower rate by myosin light chain kinase in vitro, leading to diphosphorylated RLC (40, 41). In contracting smooth muscle tissues, monophosphorylated and diphosphorylated forms of myosin RLC were also observed (34). However, because phosphorylation at Thr-18 has no effect on the velocity of myosin movement in motility assays in vitro (42), the physiological importance of diphosphorylated RLC needs clarification by further investigations.

An interesting result was observed in saponin-permeable cells in Ca2+-free buffer. RLC phosphorylation was increased in Ca2+-free buffer containing okadaic acid, a known phosphatase type 1 and 2A inhibitor (26). In addition, wortmannin did not inhibit this RLC phosphorylation. These results suggest that some low kinase activity toward RLC is independent of the Ca2+/calmodulin-dependent myosin light chain kinase pathway. Ca2+-independent RLC phosphorylation in the presence of a protein phosphatase inhibitor such as okadaic acid has also been reported for smooth muscle tissues (26). Recent studies also showed in vitro and in vivo that protein kinase C and Rho-associated kinase (Rho-kinase) may phosphorylate RLC (43-45). Although protein kinase C phosphorylated Thr-9, Ser-1, and/or Ser-2 of myosin RLC in vitro, it did not increase actin-activated Mg2+ATPase activity or myosin motility (42, 44). Smooth muscle contraction still occurred at low Ca2+ concentrations, suggesting that a Ca2+-independent isoform of protein kinase Cepsilon could conceivably phosphorylate RLC (46). On the other hand, Rho-kinase activated by GTP-bound RhoA may increase the extent of RLC phosphorylation and induce smooth muscle contraction in the absence of Ca2+ (45). Increasing RLC phosphorylation by Rho-kinase appears to be primarily indirect through the inactivation of myosin phosphatase by phosphorylation of the myosin-binding subunit of the phosphatase (47). However, very little Rho-kinase was present in Triton X-100-permeable fibers (45), and both inactive and active Rho-kinases did not appear to be localized to actomyosin-containing fibers based on immunofluorescence staining (48). Additional investigations are needed to identify specifically this Ca2+-independent kinase and its potential physiological relevance.

In summary, our results suggest that myosin light chain kinase bound to actin-containing filaments with a high affinity at its N terminus is sufficient for RLC phosphorylation and cell contraction when activated by Ca2+/calmodulin. This raises an interesting question as to how the kinase phosphorylates myosin RLC in thick filaments if it is bound to actin-containing thin filaments. Structural studies by sedimentation velocity show that axial ratios of full-length myosin light chain kinase are 18.0 and 16.8 in the absence and presence of Ca2+/calmodulin, respectively (49). Based on sedimentation velocity data, the calculated length of the recombinant smooth muscle myosin light chain kinase is 540 Å.2 Thus, the shape of a full-length myosin light chain kinase molecule is elongated either in the presence or absence of Ca2+/calmodulin. Myosin light chain kinase may reach and phosphorylate RLC on myosin thick filaments while it remains attached to actin-containing thin filaments. In smooth muscle, the surface-to-surface distance from thick and thin filaments is approximately 150 Å (50). It has been shown by small angle x-ray and neutron scattering that myosin light chain kinase containing the catalytic core and regulatory segment forms an elongated ellipsoid with a maximum linear dimension of 95 and 78 Å in the absence and presence of Ca2+/calmodulin, respectively (51). The catalytic cleft is in the middle of these ellipsoids. Smooth muscle myosin light chain kinase contains structural motifs between the N terminus and catalytic core, including the tandem repeat region and two immunoglobulin-like (Ig) and one fibronectin-like (Fn) motifs (Fig. 2A). The three-dimensional structures of individual Ig and Fn motifs are known (52, 53), and calculations show that three of these motifs would extend the catalytic core at least 130 Å. The three-dimensional structures of the tandem repeat region, the intervening sequences between the immunoglobulin-like and fibronectin-like motifs, and the N terminus of myosin light chain kinase are not known, but clearly the intervening distance between the N-terminal binding segment and the substrate-binding cleft in the catalytic core seems more than sufficient to span the 150 Å between thin and thick filaments. Although a plausible hypothesis, additional investigations are needed to understand how myosin light chain kinase bound to actin-containing filaments in cells phosphorylates myosin light chain in thick filaments.

    FOOTNOTES

* This work was supported, in part, by the Bashour Research Fund, National Institutes of Health Grant HL26043, and National Science Foundation Grant MCB-96.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Dept. of Physiology, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235-9040. Tel.: 214-648-6849; Fax: 214-648-2974; E-mail: jstull{at}mednet.swmed.edu.

2 Z. Grabarek and W. F. Stafford, personal communication.

    ABBREVIATIONS

The abbreviations used are: RLC, regulatory light chain; GFP, green fluorescent protein; MLCK, myosin light chain kinase; DN MLCK-GFP, N-terminal 2-142 residue-deleted myosin light chain kinase with a C-terminal tag of green fluorescent protein; FL MLCK-GFP, full-length myosin light chain kinase with a C-terminal tag of green fluorescent protein; MOPS, 3-(N-morpholino)propanesulfonic acid; FRAP, fluorescence recovery after photobleaching; PAGE, polyacrylamide gel electrophoresis; Cy3, cyanine 3,18-N-hydroxysuccinimidyl ester; PIPES, 1,4-piperazinediethanesulfonic acid.

    REFERENCES
Top
Abstract
Introduction
References
  1. Kamm, K. E., and Stull, J. T. (1985) Annu. Rev. Pharmacol. Toxicol. 25, 593-620[CrossRef][Medline] [Order article via Infotrieve]
  2. Sweeney, H. L., Bowman, B. F., and Stull, J. T. (1993) Am. J. Physiol. 264, C1085-C1095[Abstract/Free Full Text]
  3. Holzapfel, G., Wehland, J., and Weber, K. (1983) Exp. Cell Res. 148, 117-126[Medline] [Order article via Infotrieve]
  4. Kolodney, M. S., and Elson, E. L. (1993) J. Biol. Chem. 268, 23850-23855[Abstract/Free Full Text]
  5. Wysolmerski, R. B., and Lagunoff, D. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 16-20[Abstract]
  6. Wysolmerski, R. B., and Lagunoff, D. (1991) Am. J. Physiol. 261, C32-C40[Abstract/Free Full Text]
  7. Goeckeler, Z. M., and Wysolmerski, R. B. (1995) J. Cell Biol. 130, 613-627[Abstract]
  8. Hashimoto, Y., Sasaki, H., Togo, M., Tsukamoto, K., Horie, Y., Fukata, H., Watanabe, T., and Kurokawa, K. (1994) Biochim. Biophys. Acta 1223, 163-169[Medline] [Order article via Infotrieve]
  9. Mamiya, S., Hagiwara, M., Inoue, S., and Hidaka, H. (1989) J. Biol. Chem. 264, 8575-8579[Abstract/Free Full Text]
  10. Jian, X., Szaro, B. G., and Schmidt, J. T. (1996) J. Neurobiol. 31, 379-391[CrossRef][Medline] [Order article via Infotrieve]
  11. Kerrick, W. G., and Bourguignon, L. Y. (1984) Proc. Natl. Acad. Sci. U. S. A. 81, 165-169[Abstract]
  12. Kemp, B. E., and Stull, J. T. (1990) in Peptides and Protein Phosphorylation I (Kemp, B. E., ed), pp. 115-133, CRC Press, Inc., Boca Raton, FL
  13. Stull, J. T., Kamm, K. E., Krueger, J. K., Lin, P., Luby-Phelps, K., and Zhi, G. (1997) Adv. Second Messenger Phosphoprotein Res. 31, 141-150[Medline] [Order article via Infotrieve]
  14. Kanoh, S., Ito, M., Niwa, E., Kawano, Y., and Hartshorne, D. J. (1993) Biochemistry 32, 8902-8907[Medline] [Order article via Infotrieve]
  15. Ye, L. H., Hayakawa, K., Kishi, H., Imamura, M., Nakamura, A., Okagaki, T., Takagi, T, Iwata, A., Tanaka, T., and Kohama, K. (1997) J. Biol. Chem. 272, 32182-32189[Abstract/Free Full Text]
  16. Gallagher, P. J., and Stull, J. T. (1997) Mol. Cell Biochem. 173, 51-57[CrossRef][Medline] [Order article via Infotrieve]
  17. Shirinsky, V. P., Vorotnikov, A. V., Birukov, K. G., Nanaev, A. K., Collinge, M., Lukas, T. J., Sellers, J. R., and Watterson, D. M. (1993) J. Biol. Chem. 268, 16578-16583[Abstract/Free Full Text]
  18. Sellers, J. R., and Pato, M. D. (1984) J. Biol. Chem. 259, 7740-7746[Abstract/Free Full Text]
  19. de Lanerolle, P., Adelstein, R. S., Feramisco, J. R., and Burridge, K. (1981) Proc. Natl. Acad. Sci. U. S. A. 78, 4738-4742[Abstract]
  20. Guerriero, V., Jr., Rowley, D. R., and Means, A. R. (1981) Cell 27, 449-458[Medline] [Order article via Infotrieve]
  21. Lin, P., Luby-Phelps, K., and Stull, J. T. (1997) J. Biol. Chem. 272, 7412-7420[Abstract/Free Full Text]
  22. Stull, J. T., Lin, P., Krueger, J. K., Trewhella, J., and Zhi, G. (1998) Acta Physiol. Scand., 164, 471-482
  23. Tansey, M. G., Luby-Phelps, K., Kamm, K. E., and Stull, J. T. (1994) J. Biol. Chem. 269, 9912-9920[Abstract/Free Full Text]
  24. Kamm, K. E., and Stull, J. T. (1986) Science 232, 80-82[Medline] [Order article via Infotrieve]
  25. Colburn, J. C., Michnoff, C. H., Hsu, L. C., Slaughter, C. A., Kamm, K. E., and Stull, J. T. (1988) J. Biol. Chem. 263, 19166-19173[Abstract/Free Full Text]
  26. Obara, K., Takai, A., Ruegg, J. C., and de Lanerolle, P. (1989) Pflugers Archiv. 414, 134-138[Medline] [Order article via Infotrieve]
  27. Tansey, M. G., Hori, M., Karaki, H., Kamm, K. E., and Stull, J. T. (1990) FEBS Lett. 270, 219-221[CrossRef][Medline] [Order article via Infotrieve]
  28. Cohen, D. M., and Murphy, R. A. (1978) J. Gen. Physiol. 72, 369-380[Abstract]
  29. Hartshorne, D. J., Ito, M., and Ikebe, M. (1989) Adv. Exp. Med. Biol. 255, 269-277[Medline] [Order article via Infotrieve]
  30. Zolotukhin, S., Potter, M., Hauswirth, W. W., Guy, J., and Muzyczka, N. (1996) J. Virol. 70, 4646-4654[Abstract]
  31. Blumenthal, D. K., and Stull, J. T. (1980) Biochemistry 19, 5608-5614[Medline] [Order article via Infotrieve]
  32. Luby-Phelps, K., Hori, M., Phelps, J. M., and Won, D. (1995) J. Biol. Chem. 270, 21532-21538[Abstract/Free Full Text]
  33. Bowman, B. F., Peterson, J. A., and Stull, J. T. (1992) J. Biol. Chem. 267, 5346-5354[Abstract/Free Full Text]
  34. Persechini, A., Kamm, K. E., and Stull, J. T. (1986) J. Biol. Chem. 261, 6293-6299[Abstract/Free Full Text]
  35. Taylor, D. A., and Stull, J. T. (1988) J. Biol. Chem. 263, 14456-14462[Abstract/Free Full Text]
  36. Adelstein, R. S., and Klee, C. B. (1981) J. Biol. Chem. 256, 7501-7509[Abstract/Free Full Text]
  37. Nakanishi, S., Kakita, S., Takahashi, I., Kawahara, K., Tsukuda, E., Sano, T., Yamada, K., Yoshida, M., Kase, H., and Matsuda, Y. (1992) J. Biol. Chem. 267, 2157-2163[Abstract/Free Full Text]
  38. Powis, G., Bonjouklian, R., Berggren, M. M., Gallegos, A., Abraham, R., Ashendel, C, Zalkow, L., Matter, W. F., Dodge, J., and Grindey, G. (1994) Cancer Res. 54, 2419-2423[Abstract]
  39. Pearson, R. B., Misconi, L. Y., and Kemp, B. E. (1986) J. Biol. Chem. 261, 25-27[Abstract/Free Full Text]
  40. Ikebe, M., and Hartshorne, D. J. (1985) J. Biol. Chem. 260, 10027-10031[Abstract/Free Full Text]
  41. Ikebe, M., Hartshorne, D. J., and Elzinga, M. (1986) J. Biol. Chem. 261, 36-39[Abstract/Free Full Text]
  42. Umemoto, S., Bengur, A. R., and Sellers, J. R. (1989) J. Biol. Chem. 264, 1431-1436[Abstract/Free Full Text]
  43. Ikebe, M., Hartshorne, D. J., and Elzinga, M. (1987) J. Biol. Chem. 262, 9569-9573[Abstract/Free Full Text]
  44. Bengur, A. R., Robinson, E. A., Appella, E., and Sellers, J. R. (1987) J. Biol. Chem. 262, 7613-7617[Abstract/Free Full Text]
  45. Kureishi, Y., Kobayashi, S., Amano, M., Kimura, K., Kanaide, H., Nakano, T., Kaibuchi, K., and Ito, M. (1997) J. Biol. Chem. 272, 12257-12260[Abstract/Free Full Text]
  46. Walsh, M. P., Horowitz, A., Clement-Chomienne, O., Andrea, J. E., Allen, B. G., and Morgan, K. G. (1996) Biochem. Cell Biol. 74, 485-502[Medline] [Order article via Infotrieve]
  47. Kimura, K., Ito, M., Amano, M., Chihara, K., Fukata, Y., Nakafuku, M., Yamamori, B, Feng, J., Nakano, T., Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) Science 273, 245-248[Abstract]
  48. Matsui, T., Amano, M., Yamamoto, T., Chihara, K., Nakafuku, M., Ito, M., Nakano, T, Okawa, K., Iwamatsu, A., and Kaibuchi, K. (1996) EMBO J. 15, 2208-2216[Abstract]
  49. Mabuchi, Y., Stafford, W. F., and Grabarek, Z. (1998) Biophys. J. 74, A38 (abstr.)
  50. Somlyo, A. P., Devine, C. E., Somlyo, A. V., and Rice, R. V. (1973) Philos. Trans. R. Soc. Lond.-Biol. Sci. 265, 223-229[Medline] [Order article via Infotrieve]
  51. Krueger, J. K., Olah, G. A., Rokop, S. E., Zhi, G., Stull, J. T., and Trewhella, J. (1997) Biochemistry 36, 6017-6023[CrossRef][Medline] [Order article via Infotrieve]
  52. Holden, H. M., Ito, M., Hartshorne, D. J., and Rayment, I. (1992) J. Mol. Biol. 227, 840-851[Medline] [Order article via Infotrieve]
  53. Huber, A. H., Wang, Y. M., Bieber, A. J., and Bjorkman, P. J. (1994) Neuron 12, 717-731[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.